Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer.
Sipola J, Munzur AD, Kwan EM, Seo CCY, Hauk BJ, Parekh K, Liao YJR, Bernales CQ, Donnellan G, Bloise I, Fung E, Ng SWS, Wang G, Vandekerkhove G, Nykter M, Annala M, Maurice-Dror C, Chi KN, Herberts C, Wyatt AW, Takeda DY. Sipola J, et al. Among authors: annala m. Cancer Res. 2024 Dec 9. doi: 10.1158/0008-5472.CAN-24-2052. Online ahead of print. Cancer Res. 2024. PMID: 39652574
Sensitive Detection of Urothelial Cancer via High-volume Urine DNA Analysis.
Nikkola J, Ryyppö L, Vuorinen J, Kallio H, Selin H, Jämsä P, Åkerla J, Virtanen T, Pekkarinen T, Kaipia A, Pulkkinen J, Vandekerkhove G, Müller DC, Wyatt AW, Black PC, Nykter M, Veitonmäki T, Annala M. Nikkola J, et al. Among authors: annala m. Eur Urol. 2025 Jan;87(1):86-88. doi: 10.1016/j.eururo.2024.10.014. Epub 2024 Oct 22. Eur Urol. 2025. PMID: 39443274 No abstract available.
Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer.
Kallio HM, Savolainen K, Virtanen T, Ryyppö L, Selin H, Martikainen P, Staff S, Kivinummi K, Sipola J, Vuorinen J, Nikkola J, Nykter M, Auranen A, Annala M. Kallio HM, et al. Among authors: annala m. Life Sci Alliance. 2024 Apr 5;7(6):e202402658. doi: 10.26508/lsa.202402658. Print 2024 Jun. Life Sci Alliance. 2024. PMID: 38580393 Free PMC article.
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Schönlau E, Bernales CQ, Donnellan G, Ng SWS, Sumiyoshi T, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Parimi S, Lavoie JM, Hardy E, Soleimani M, Nappi L, Eigl BJ, Kollmannsberger C, Taavitsainen S, Nykter M, Tolmeijer SH, Boerrigter E, Mehra N, van Erp NP, De Laere B, Lindberg J, Grönberg H, Khalaf DJ, Annala M, Chi KN, Wyatt AW. Fonseca NM, et al. Among authors: annala m. Nat Commun. 2024 Feb 28;15(1):1828. doi: 10.1038/s41467-024-45475-w. Nat Commun. 2024. PMID: 38418825 Free PMC article.
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.
Warner EW, Van der Eecken K, Murtha AJ, Kwan EM, Herberts C, Sipola J, Ng SWS, Chen XE, Fonseca NM, Ritch E, Schönlau E, Bernales CQ, Donnellan G, Munzur AD, Parekh K, Beja K, Wong A, Verbeke S, Lumen N, Van Dorpe J, De Laere B, Annala M, Vandekerkhove G, Ost P, Wyatt AW. Warner EW, et al. Among authors: annala m. Nat Cancer. 2024 Jan;5(1):114-130. doi: 10.1038/s43018-023-00692-y. Epub 2024 Jan 4. Nat Cancer. 2024. PMID: 38177459
Advancing chemical safety assessment through an omics-based characterization of the test system-chemical interaction.
Del Giudice G, Migliaccio G, D'Alessandro N, Saarimäki LA, Torres Maia M, Annala ME, Leppänen J, Mӧbus L, Pavel A, Vaani M, Vallius A, Ylä-Outinen L, Greco D, Serra A. Del Giudice G, et al. Among authors: annala me. Front Toxicol. 2023 Nov 9;5:1294780. doi: 10.3389/ftox.2023.1294780. eCollection 2023. Front Toxicol. 2023. PMID: 38026842 Free PMC article.
Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ, Jaatinen S, Hartewig A, Tiihonen AM, Annala M, Salonen I, Valkonen M, Simola V, Vuorinen EM, Kivinen A, Rauhala MJ, Nurminen R, Maass KK, Lahtela SL, Jukkola A, Yli-Harja O, Helén P, Pajtler KW, Ruusuvuori P, Haapasalo J, Zhang W, Haapasalo H, Nykter M. Rautajoki KJ, et al. Among authors: annala m. Acta Neuropathol Commun. 2023 Nov 6;11(1):176. doi: 10.1186/s40478-023-01669-9. Acta Neuropathol Commun. 2023. PMID: 37932833 Free PMC article.
Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, Beja K, Mizuno K, Ku S, Fazli L, Eastham J, Taplin ME, Simko J, Halabi S, Morris MJ, Gleave ME, Wyatt AW, Beltran H. Sumiyoshi T, et al. Among authors: annala m. J Natl Cancer Inst. 2024 Jan 10;116(1):115-126. doi: 10.1093/jnci/djad184. J Natl Cancer Inst. 2024. PMID: 37676819 Free PMC article.
ESPERANTO: a GLP-field sEmi-SuPERvised toxicogenomics metadAta curatioN TOol.
Di Lieto E, Serra A, Inkala SI, Saarimäki LA, Del Giudice G, Fratello M, Hautanen V, Annala M, Federico A, Greco D. Di Lieto E, et al. Among authors: annala m. Bioinformatics. 2023 Jun 1;39(6):btad405. doi: 10.1093/bioinformatics/btad405. Bioinformatics. 2023. PMID: 37354497 Free PMC article.
Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.
Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM, Bassetti M, Blitzer G, Floberg J, Sjöström M, Quigley DA, Dehm SM, Armstrong AJ, Beltran H, McKay RR, Feng FY, O'Regan R, Wisinski KB, Emamekhoo H, Wyatt AW, Lang JM, Zhao SG. Helzer KT, et al. Among authors: annala m. Ann Oncol. 2023 Sep;34(9):813-825. doi: 10.1016/j.annonc.2023.06.001. Epub 2023 Jun 16. Ann Oncol. 2023. PMID: 37330052 Free PMC article.
83 results